PNC-27: what the cancer cell studies show, and what has never been tested

PNC-27 is a laboratory-designed peptide, not a natural one. It has two halves. The PNC-27 p53 half is residues 12 to 26 of human p53, the part of the tumour-suppressor protein that binds mdm-2 (called HDM-2 in humans), the enzyme that normally marks p53 for destruction. The second is penetratin, a 17-residue sequence rich in positively charged amino acids that carries cargo across cell membranes and, usefully, helps hold the p53 fragment in the alpha-helical shape it needs to bind its target.

The founding work was published in 2001 by Martin Kanovsky, Matthew Pincus and colleagues. They synthesised three peptides from the mdm-2 binding domain of p53, each joined at its carboxyl terminus to penetratin. All three killed human cancer cells in culture while a control peptide carrying the same penetratin sequence did not, and none of them affected normal cells, including human cord-blood-derived stem cells. Crucially, the peptides killed p53-null cancer cells as effectively as cells with normal or mutant p53, and cell death was not accompanied by the usual apoptosis-associated proteins, so the authors concluded that the effect did not run through p53 activity itself ^[1].

Our guide to what research peptides are explains what the research-use label means. PNC-27 sits in an unusual category among the compounds peptide stores sell: unlike recovery or metabolic peptides such as BPC-157 or MOTS-c, it was designed from the start to kill cells, and it is bought by people who have read that the anti-cancer peptide PNC-27 kills tumour cells. That claim needs handling carefully, and the rest of this page is about exactly how far the evidence goes. The short version of the PNC-27 peptide story is a well-documented laboratory mechanism and an empty clinical record.

The PNC-27 HDM-2 mechanism proposed by the research group is specific and unusual. HDM-2 is normally an intracellular enzyme, but the group reported finding significant levels of it in the plasma membranes of a variety of cancer cell lines and not in the membranes of untransformed lines. In a 2010 study they showed that the three-dimensional structure of the p53 residues in PNC-27 superimposes on the structure of the same residues bound to HDM-2, that PNC-27 colocalises with membrane-bound HDM-2, and, in the decisive experiment, that transfecting untransformed MCF-10-2A cells with a membrane-targeted full-length HDM-2 made those previously resistant cells susceptible to PNC-27 ^[2].

What happens after binding is described as membranolysis rather than apoptosis. A 2022 study used immuno-scanning electron microscopy with differently sized gold particles labelling PNC-27 and HDM-2 separately, and reported roughly one-to-one ratios of the two labels arranged in layered, ring-shaped structures at pores near the cell surface. No pores formed in untransformed fibroblasts treated the same way ^[3]. The group calls this pore-forming mechanism poptosis, and has argued it is a distinct way to kill cancer cells without affecting normal ones ^[4].

An independent group at City of Hope reached a similar destination by a different route in a 2020 Leukemia paper. They reported that membrane HDM2 is expressed on human and mouse acute myeloid leukaemia blasts, including leukaemia stem cell-enriched populations, but not on normal haematopoietic stem cells, and that PNC-27 binding to membrane HDM2 enhanced its interaction with E-cadherin, leading to E-cadherin degradation, membrane damage and cell death. PNC-27 killed both bulk blasts and leukaemia stem cells in primary and secondary transplant experiments while sparing normal haematopoietic stem cell activity ^[5]. Independent replication by a group with no stake in the peptide is the strongest single piece of evidence in this literature.

There is also mitochondrial work. A 2024 study reported that PNC-27 interacts with mitochondrial membranes and causes mitochondrial disruption alongside its action at the plasma membrane ^[6], and an earlier study found that chondroitin sulfate acts as a molecular portal preferentially mediating the killing of tumour cells by penetratin-directed mitochondria-disrupting peptides ^[7].

Most PNC-27 peptide cancer research follows one thread, and before listing results the framing matters. Every study below was done in cell culture or in mice. Killing a cancer cell line in a dish is a routine achievement; bleach does it. What makes this literature interesting is the reported selectivity, and what makes it insufficient is that selectivity in a dish tells you nothing about what a peptide does in a living person with a circulatory system, an immune system and a liver.

Leukaemia: the 2020 Leukemia study described above found selective killing of AML blasts and leukaemia stem cells with sparing of normal haematopoietic stem cells in transplant experiments ^[5]. An earlier study reported that PNC-27 induced necrosis in leukaemia cells but not in normal haematopoietic cells, again tracking membrane HDM-2 levels ^[8], and a 2014 study reported the same for a poorly differentiated non-solid human leukaemia line ^[9].

Ovarian cancer: a 2015 study tested PNC-27 ex vivo on epithelial ovarian cancer taken directly from patients rather than on established cell lines ^[10], a 2020 study linked necrosis of ovarian cancer cell lines to high membrane HDM-2 expression ^[11], and a 2017 study reported synergy between PNC-27 and paclitaxel in ovarian cancer models ^[12].

Colon and cervical cancer: a 2021 study examined targeting of H/MDM-2 in human colon cancer cells and stem-like colonic progenitor cells ^[13], and a 2025 study reported that PNC-27 killed cervical cancer cells but not normal cervical cells ^[14].

The peptide must be intact: a 2010 study reported that PNC-27 induces tumour cell lysis as the whole peptide rather than through a fragment ^[15], and the original NMR solution structure work established that the p53-derived region adopts the binding conformation that makes the design work ^[16]. Taken together this is a coherent, long-running preclinical programme. It is not clinical evidence, and the distinction is not a technicality.

Searches for PNC-27 human trials have a short answer. There is no published clinical trial of PNC-27 in humans. There is no registered PNC-27 trial on ClinicalTrials.gov. No regulator has authorised it for investigational use in patients that we can find, and it has no approval anywhere.

The closest the literature comes to people is the 2015 ex vivo study, in which ovarian cancer tissue taken from patients was treated with PNC-27 outside the body ^[10]. That is a better model than an immortalised cell line, and it is still a dish.

Commercial interests exist: the peptides were supplied for at least one study by Oncolyze, Inc. ^[5], and the inventors of PNC-27 and PNC-28 declare patents on them ^[3]. A company holding a patent is not evidence that a compound works in people. Anyone considering PNC-27 because of a cancer diagnosis should discuss it with their oncology team; this page is a summary of published research, not medical advice, and nothing here indicates that PNC-27 treats cancer in humans.

The question does not have a human answer. In cell culture, PNC-27 kills susceptible cells within hours of exposure, which is what you would expect from a pore-forming mechanism rather than one that has to change gene expression ^{[2] [3]}. Mouse experiments have run over days to weeks ^[5].

There is no published pharmacokinetic study of PNC-27 in people, so nobody can say how long it circulates, where it goes or how quickly it is cleared after an injection.

No PNC-27 dosage has been established for people. What follows describes laboratory and animal experiments and is not a recommendation; no dose of PNC-27 has been tested for safety or effect in a human. Cell studies typically expose cultures to micromolar concentrations of the peptide for hours and then measure cell lysis, with untransformed cell lines run alongside as the selectivity control ^{[1] [2] [3]}. The mouse work in leukaemia used repeated systemic dosing over days in transplant models ^[5].

Two practical points follow from the chemistry. PNC-27 is a 32-residue peptide of about 4032 g/mol, so a milligram is far fewer molecules than the same mass of a short peptide, and the published work insists the peptide must be intact to work ^[15], meaning a partly degraded vial is not simply a weaker vial. If you need to convert a stated vial content into a concentration, our peptide calculator and the PNC-27 calculator page do the arithmetic, though the arithmetic is the least uncertain part of this.

Published work used the peptide in solution applied to cells, or given systemically to mice ^{[2] [5]}. Suppliers sell PNC-27 as a lyophilised powder for reconstitution. There is no published human study of any route, no oral data, and no nebulised or topical data. A 2022 study conjugated PNC-27 to iron oxide nanoparticles as a targeting agent for early cancer diagnosis in vitro ^[17], and another used PNC-27 as a targeting ligand to improve the delivery of a liposomal doxorubicin formulation to HDM2-expressing cells ^[18], which is a reminder that much of the recent interest treats the peptide as a homing device rather than as a drug in itself.

There are no human safety data. None. Anything you read describing PNC-27 side effects in people is not based on published research.

The animal and cell literature reports selectivity: normal cells, including cord-blood stem cells ^[1], untransformed fibroblasts ^[3] and normal haematopoietic stem cells ^[5], were spared in the conditions tested. That is the central claim of the programme and it has been reproduced by an independent group ^[5]. But selectivity in these experiments depends entirely on the premise that HDM-2 sits in cancer cell membranes and not normal ones ^[2]. If that distinction is less absolute in a living body than in the cell lines tested, a pore-forming peptide circulating through every tissue is a bad thing to have.

Nothing is known about what repeated PNC-27 exposure does to the kidney, the liver, blood cells or the immune system in people, about immunogenicity, or about interactions with chemotherapy other than the paclitaxel synergy reported in cell work ^[12]. There is also no evidence at all for any non-cancer use: we found no study of PNC-27 and muscle, recovery, ageing or metabolism.

PNC-27 is not an approved medicine in the UK, US, EU, Canada, Australia or New Zealand as far as we are aware, and it has no registered clinical trial. It is sold as a research chemical. Selling or supplying an unapproved compound with claims that it treats cancer is a regulatory offence in most of the markets we cover, and it is worth noticing whether a store makes such claims: it tells you something about the store.

For the rules that apply where you live, see our legal status overview and the country pages for the UK, the US and Canada. Our news coverage of the FDA advisory committee on compounded peptides describes how the regulatory position on research-use peptides has been tightening. We have not confirmed PNC-27’s status on the WADA Prohibited List; it has no performance-enhancing rationale.

PNC-27 is supplied as a freeze-dried powder. Peptides are generally kept cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. See how to store peptides and bacteriostatic water. Because the published work reports that the intact peptide is what causes cell lysis ^[15], degradation matters more here than with peptides whose fragments retain activity.

At 32 residues PNC-27 is a long peptide to synthesise, and the penetratin half is full of arginine and lysine, which makes purification harder and truncated sequences more likely. A certificate of analysis should show a mass close to 4032 g/mol and a purity figure supported by an actual chromatogram, not a claim.

Compare PNC-27 prices across the suppliers we track, including listings in the UK, the US and Australia. Read our guides to how to read a peptide COA, third-party peptide testing and how to spot a fake peptide supplier before buying anything, and see which stores publish independent results on our third-party tested suppliers list. Why identical-looking vials differ so much in price is covered in peptide prices explained.